Stock Forecast

  Integra LifeSciences Holdings Corporation ( IART) Stock. Should you Buy or Sell?    $ 49.59

1.14 (2.25 %)

Integra LifeSciences Holdings Corporation Analysis

Updated on 10-09-2022
Symbol IART
Price $49.59
Beta 1.089
Volume Avg. $510.05 thousand
Market Cap $4.14 B
52 Week Range $46.46 - $74.98

Integra LifeSciences Holdings Corporation opened the day at $49.59 which is +'2.25 % on yesterday's close. Integra LifeSciences Holdings Corporation has a 52 week high of $74.98 and 52 week low of $46.46, which is a difference of $28.52. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $4.14 B and total net profit is $1542448000 which means the company is trading at 2.68 times profit to market capitalization. Theoretically, if you were to buy Integra LifeSciences Holdings Corporation for $4.14 B, it would take 15 years to get your money back. Integra LifeSciences Holdings Corporation are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Integra LifeSciences Holdings Corporation Stock Forecast - Is Integra LifeSciences Holdings Corporation a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreBuy
PE ScoreStrong Buy
PB ScoreStrong Buy
Overall RecommendationStrong Buy

Growth and Value

PE Ratio 25.301
Dividend Yiel 0.000
Net Profit Margin 0.106

Valuing Integra LifeSciences Holdings Corporation

Price Book Value Ratio 2.483 Price To Book Ratio 2.483
Price To Sales Ratio 2.632 Price Earnings Ratio 24.800

How liquid is Integra LifeSciences Holdings Corporation

Current Ratio 3.848
Quick Ratio 2.316


Debt Ratio 0.557 Debt Equity Ratio 1.260
Long Term Debt To Capitalization 0.499 Total Debt To Capitalization 0.508

Latest news about Integra LifeSciences Holdings Corporation

Integra LifeSciences Announces Participation in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the following investor conferences:

Date : 23/08/2022

Integra LifeSciences Holdings Corporation (IART) CEO Jan De Witte on Q2 2022 Results - Earnings Call Transcript

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2022 Earnings Conference Call July 27, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Glenn Coleman - Chief Operating Officer Carrie Anderson - Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Joanne Wuensch - Citi Sam Brodovsky - Truist Matt Miksic - Barclays Craig Bijou - Bank of America Jayson Bedford - Raymond James Drew Ranieri - Morgan Stanley Operator Good day, and welcome to the Integra LifeSciences Second Quarter 2022 Financial Results Conference Call. Today's conference is being recorded.

Date : 27/07/2022

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Date : 27/07/2022

Integra LifeSciences to Host Second Quarter 2022 Financial Results Conference Call on July 27, 2022

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- ) Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial results on Wednesday, July 27, 2022, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Date : 01/07/2022

Here's Why Investors Should Retain Integra (IART) Stock for Now

Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.

Date : 01/06/2022

About Integra LifeSciences Holdings Corporation

CEO : Mr. Peter Arduini
Sector : Healthcare
Industry : Medical Devices

Website :

Exchange : NASDAQ Global Select

Description :

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

My Newsletter

Sign Up For Updates & Newsletters